Eli Lilly's third-quarter report shows a company whose core franchise is still accelerating. Revenue beat expectations, the full-year sales outlook rose to $91 billion to $92 billion from $85 billion to $87 billion, and the shares climbed about 7% on Thursday. Mounjaro's worldwide revenue rose 65% to $10.72 billion, against analyst expectations of $10.10 billion, and Zepbound brought in $5.35 billion, up 49% from a year earlier. Those are strong numbers, and they deserve to be read as evidence of durable demand rather than a single good quarter.

The more interesting signal is the one the market may be discounting. Foundayo, the obesity pill that won U.S. approval in April, generated $184 million in third-quarter sales, short of the roughly $229 million analysts forecast. Lilly's CFO said prescriptions and new patients doubled from the prior quarter, and that about 4 in 10 patients starting an oral obesity medicine choose Foundayo. Those are encouraging trends, but a launch that grows quickly while still missing expectations deserves scrutiny, especially in a head-to-head contest with Novo's oral drug, which reached the market in January.

Pricing is the other pressure point. Realized prices in the U.S. fell 7% for the quarter, driven mainly by Zepbound, and outside the U.S. prices dropped 29%. Lilly attributes part of the pressure to a drug pricing deal struck with the Trump administration last year, and it highlights Medicare's decision to cover GLP-1s for weight loss under a temporary pilot starting in July. Volume is covering the gap for now, with U.S. volume up 41%, but a company whose growth depends on selling more units at lower prices should be asked how long that equation holds.

Lilly's market share claims are striking: 63% of the U.S. obesity and diabetes drug market in the third quarter, compared with Novo's 36.6%. CEO Dave Ricks estimates that only 3% to 10% of eligible patients access obesity care in the U.S., and he calls the room for expansion "dramatic." That may prove true, but it is the CEO's estimate, and investors should treat it as a forecast rather than a settled fact. The company's acquisitions, including the agreement to buy Merida Biosciences, suggest it is already looking beyond this single franchise.

My recommendation to regulators and investors is the same: keep the pricing and coverage questions in plain view. Lilly's results are impressive, but the sustainability of its growth depends on whether volume can keep outrunning lower prices, and on whether Foundayo can close the gap with analyst expectations. Those are the numbers to watch in the next quarter.